<DOC>
	<DOCNO>NCT02958319</DOCNO>
	<brief_summary>Patients rheumatoid arthritis positive antibody carbamylated protein ( anti-CarP ) severe clinical course . The primary objective study adult subject RA follow : To explore clinical difference activity index ( DAS28-ESR ) 6 , 12 18 month follow accord anti-CarP status .</brief_summary>
	<brief_title>Clinical Follow-up Anti-Carbamylated Antibody Status Rheumatoid Arthritis</brief_title>
	<detailed_description>Clinical follow-up Anti-Carbamylated Antibody Status Rheumatoid Arthritis patient 6 , 12 18 month . Concept Patients rheumatoid arthritis positive antibody carbamylated protein ( anti-CarP ) severe clinical course . Background The immune base pathophysiology rheumatoid arthritis one study . We already know citrullinated peptide antigen induce antibody formation subsequent [ LVG1 ] anti-cyclic citrullinated peptide ( anti-CCP ) . In patient explain clinical manifestation . However also apparent group patient rheumatoid arthritis anti-CCP antibody . It possible presence variety antigen expose disease , perhaps different clinical presentation associate . The use anti-cyclic citrullinated peptide ( anti-CCP ) include classification criterion rheumatoid arthritis developed American College Rheumatology 2010 generate presence two sub-groups patient rheumatoid arthritis , positive negative anti-cyclic citrullinated peptide . It important study presence anti-CCP antibody rheumatoid arthritis population influence clinical behavior response treatment . In early undifferentiated arthritis , presence anti-CCP antibody predict presence erosion course disease . On hand , patient anti-CCP tend good response treatment methotrexate . Initially think obvious pathophysiological link rheumatoid arthritis citrullinated peptide lead formation antibody apparent cause clinical manifestation , soon demonstrate group patient clinical manifestation rheumatoid arthritis anti-CCP antibody genesis explain citrullination . Then possible diversity antigen expose illness perhaps different clinical presentation associate one combination . So actually , study attempt show possible antigen involve rheumatoid arthritis one use homocitrulline antigenic basis rheumatoid arthritis pathophysiology . The carbamylation homocitrullination posttranslational modification protein occur amino acid lysine reacts cyanate non-enzyme-mediated process generate homocitrulline . Mydel , Bokarewa cols . demonstrate immunization mouse homocitrulline- citrulline-containing peptide lead development erosive arthritis follow intra-articular injection homocitrulline-containing peptide propose homocitrulline induce activation T cell key mechanism pathogenesis autoimmune arthritis serve initial trigger event neo-epitope recognition citrulline contain peptide . Recently It show rheumatoid arthritis patient homocitrullinated protein joint trigger inflammatory response formation antibody homocitrulline . Shi et al . show study 571 rheumatoid arthritis patient 350 healthy subject follow statement : - The anti-carbamylated peptide ( Anti-CARP ) antibodies different anti-cyclic citrullinated peptide cross-react . - The Anti-CARP antibody present serum patient rheumatoid arthritis . - Anti-CARP antibody find serum patient without anti-CCP . - The Anti-CARP antibody associate increased progression radiographic damage . Thus , autoantibody recognize carbamylated protein ( anti-CarP ) promise new serological marker ACPA negative Rheumatoid Arthritis associate severe clinical course . Hypothesis Patients rheumatoid arthritis positive antibody carbamylated protein ( anti-CarP ) severe clinical course elevate cardiovascular risk . Design It parallel study clinical follow-up , observational . Description Subject Population ( ) - Patients older 18 year old , gender , rheumatoid arthritis diagnosis accord ACR EULAR 2010 classification accept sign informed consent see Rheumatology Clinic Hospital Universitario `` Dr. José Eleuterio González '' , Monterrey , NL . México . - Exclusion : Chronic kidney disease pregnant patient Assessment Tools Procedures - DAS-28 ESR - Lipid profile Length Study Months - 18 Primary Endpoints - Clinical activity measure DAS28-ESR patient rheumatoid arthritis accord antibody carbamylated protein ( anti-CarP ) status 6 , 12 18 month Secondary Endpoints - Number accumulative dose DMARDs accord antibody carbamylated protein ( anti-CarP ) status 6 , 12 18 month - Cardiovascular risk accord antibody carbamylated protein ( anti-CarP ) status 6 , 12 18 month Clinical Information - Total number subject 262 - Number subject treatment arm 131 - Study Duration Per Patient ( Months ) 18 Primary Objective The primary objective study adult subject RA follow : 1 . To explore clinical difference activity index ( DAS28-VSG ) 6 , 12 18 month follow accord anti-CarP status Study Secondary Objective ( ) One secondary objective follow : - To investigate remission rate ( DAS28-VSG ) accord anti-CarP status - Other secondary objective follow : - To compare percentage subject DAS28-VSG LDA 6 , 12 18 month accord anti-CarP status - To compare accumulative dose prednisone group accord anti-CarP status - To compare number dos DMARD´s use treat RA group accord ant CarP status Study Design - Prospective , Non-Randomized , Open Label - Inception Cohort Study Study Primary Efficacy Endpoints The primary efficacy endpoitns follow : - The percentage subject meet DAS28-ESR &lt; 2.6 6 , 12 18 month Anti CarP+ve arm compare Anti CarP-ve arm Study Secondary Efficacy Endpoints The secondary efficacy endpoint follow : - Percentage subject DAS28-esr LDA 6 , 12 18 month 6 , 12 18 month Anti CarP+ve arm compare Anti CarP-ve arm - Median acummulative dose prednisone 18 month 6 , 12 18 month Anti CarP+ve arm compare Anti CarP-ve arm - Mean number dos DMARD´s use treat RA enrrollment 6 , 12 18 month Anti CarP+ve arm compare Anti CarP-ve arm - Cardiovascular risk accord anti-CarP status Study Sample Size Calculation A total 262 subject follow study . According pilot study find 12 month remission rate Anti CarP+ve 33 % arm compare Anti CarP-ve arm 50 % , difference 17 % remission rate 12 month follow-up . One hundred thirty-three patient need per group . A 2 group continuity correct chi square test 2-sided significance level ( alpha ) 0.05 use compare sample size 0.2 ( beta ) power . Study Statistical Methods Descriptive statistic categorical numerical variable use . Categorical variable express frequency percentage ; comparison do chi square test . Numerical variable , normality test describe mean median SD IQR correspond , respectively . For primary end point , chi square test percentage DAS28-ESR remission group compare . For secondary end point compare test Mann Whitnney U mean median accumulative dose prednisone number DMARD use .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Rheumatoid arthritis patient accord ACR EULAR 2010 classification accept sign informed consent Chronic kidney disease pregnant patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>